-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|December 6, 2023

Strategies to Manage Medication Costs and Waste

Russell P. Gollard, MD, FACP, discusses strategies for mitigating the high costs of expensive medications, addressing concerns of medication waste and hoarding.

Episodes in this series

EP. 1 Management Insights for Patients With Hemophilia

EP. 1 Management Insights for Patients With Hemophilia

EP. 2 Coverage Decisions for Expensive Hemophilia Treatments

EP. 2 Coverage Decisions for Expensive Hemophilia Treatments

EP. 3 Impact of ICER Reports on Hemophilia Treatment Decisions

EP. 3 Impact of ICER Reports on Hemophilia Treatment Decisions

EP. 4 Enhancing Provider Access and Expertise for Rare Disease Care

EP. 4 Enhancing Provider Access and Expertise for Rare Disease Care

EP. 5 Factors Impacting Hemophilia A Care Costs

EP. 5 Factors Impacting Hemophilia A Care Costs

EP. 6 Collaborative Strategies in Hemophilia A Care Cost Management

EP. 6 Collaborative Strategies in Hemophilia A Care Cost Management

EP. 7 Strategies to Manage Medication Costs and Waste

EP. 7 Strategies to Manage Medication Costs and Waste

EP. 8 Adapting to Novel Hemophilia A Treatments

EP. 8 Adapting to Novel Hemophilia A Treatments

EP. 9 Comprehensive Insights into Hemophilia A: Prevalence, Clinical Impact, and Economic Considerations

EP. 9 Comprehensive Insights into Hemophilia A: Prevalence, Clinical Impact, and Economic Considerations

EP. 10 Evolution of the Hemophilia A Treatment Landscape: Innovations and Guidelines

EP. 10 Evolution of the Hemophilia A Treatment Landscape: Innovations and Guidelines

EP. 11 Hemophilia A Treatment Factors and Outcomes

EP. 11 Hemophilia A Treatment Factors and Outcomes

EP. 12 Prophylactic Treatment Challenges and Considerations for Hemophilia A

EP. 12 Prophylactic Treatment Challenges and Considerations for Hemophilia A

EP. 13 Consequences of Nonadherence in Hemophilia A

EP. 13 Consequences of Nonadherence in Hemophilia A

EP. 14 Advancements in Hemophilia A Therapies

EP. 14 Advancements in Hemophilia A Therapies

EP. 15 Comparing Hemophilia A Therapies: Efficacy and Safety Insights

EP. 15 Comparing Hemophilia A Therapies: Efficacy and Safety Insights

EP. 16 Real-World Insights: Factor vs Emicizumab in Hemophilia A

EP. 16 Real-World Insights: Factor vs Emicizumab in Hemophilia A

EP. 17 Emicizumab Dosing: Prophylaxis and Bleeding Management

EP. 17 Emicizumab Dosing: Prophylaxis and Bleeding Management

EP. 18 Optimizing Hemophilia Treatment: Strategies and Adherence

EP. 18 Optimizing Hemophilia Treatment: Strategies and Adherence

EP. 19 Advancements in Hemophilia A Therapies: Altuviiio and Roctavian

EP. 19 Advancements in Hemophilia A Therapies: Altuviiio and Roctavian

EP. 20 Advancements in Hemophilia A Treatment: Fitusiran and the Evolving Landscape

EP. 20 Advancements in Hemophilia A Treatment: Fitusiran and the Evolving Landscape

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Screening, Risk Stratification, and the Multidisciplinary Care Model for MASH

ByNadege Gunn, MD

June 30th 2026

Experts featured in this series.

Beyond Brand vs. Generic: What Really Drives Treatment Decisions After Repeated Failures

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 30th 2026 | Updated: June 16th 2026

MASH in Focus: How Patient Awareness, Clinical Empowerment, and Research Have Transformed the Field

ByNadege Gunn, MD

June 30th 2026

Experts featured in this series.

When Treatment Isn't Working: Defining Failure and Charting the Next Steps in Psychiatric Care

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 30th 2026 | Updated: June 16th 2026

Diagnosing and Assessing Atopic Dermatitis: Tools, Scoring Systems, and Patient-Centered Goal Setting

ByAngela J. Lamb, MD

June 29th 2026

Trending on AJMC

Orca-T Gains FDA Approval for Matched Donor Stem Cell Transplant

Ocrelizumab Led to Declines in Immunoglobulins in Patients With MS

Racial Gaps in Cancer Pain Management Persist in Community Care: Ila Sruti, MPH

House Panel Advances Bills to Expand Veterans’ Health Care Access

Upcoming 2026-2027 Vaccine Season: Deals, Data, and an FDA Vote